Evidence map›Paper›PMID 24835231›Full record

ArticlePloS one2014

Associations of polymorphisms in histidine decarboxylase, histamine N-methyltransferase and histamine receptor H3 genes with breast cancer.

Gong-Hao He, Jia-Ji Lin, Wen-Ke Cai, Wen-Mang Xu, Zheng-Ping Yu, Sun-Jun Yin, Can-Hu Zhao, Gui-Li Xu

Open access · goldAbstract readControlled Clinical Trial
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Histamine receptors and cancer pharmacology: an update.British journal of pharmacology · 2020
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Gong-Hao HeDepartment of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming, Yunnan, China.
Jia-Ji LinDepartment of neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Wen-Ke CaiDepartment of Cardio-Thoracic Surgery, Kunming General Hospital of Chengdu Military Region, Kunming, Yunnan, China.
Wen-Mang XuDepartment of Pathology, Kunming General Hospital of Chengdu Military Region, Kunming, Yunnan, China.
Zheng-Ping YuDepartment of Labour Hygiene, College of Military Preventive Medicine, Third Military Medical University, Chongqing, China.
Sun-Jun YinDepartment of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming, Yunnan, China.
Can-Hu ZhaoDepartment of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming, Yunnan, China.
Gui-Li XuDepartment of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming, Yunnan, China.
Kunming General Hospital of Chengdu Military Command · CNAir Force Medical University · CNArmy Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously found that genetic polymorphisms in gene coding for histamine H4 receptors were related to the risk and malignant degree of breast cancer. The roles of polymorphisms in other histamine-related genes, such as histidine decarboxylase (HDC), histamine N-methyltransferase (HNMT) and histamine H3 receptor (HRH3), remain unexplored. The aim of this study is to analyze the clinical associations of polymorphisms in HDC, HNMT and HRH3 with breast cancer. Two hundred and one unrelated Chinese Han breast cancer patients and 205 ethnicity-matched health controls were recruited for case-control investigation. Genomic DNA from the participants was extracted and 5 single nucleotide polymorphisms (SNPs) in HDC, HNMT and HRH3 were genotyped. We found that polymorphisms of HNMT and HRH3 were irrelevant with breast cancer in the present study. However, the T allele of rs7164386 in HDC significantly decreased the risk of breast cancer (adjusted odds ratios [ORs], 0.387; 95% confidence intervals [CIs], 0.208-0.720; P = 0.003). Furthermore, for HDC haplotypes, the CG haplotype of rs7164386-rs7182203 was more frequent among breast cancer patients (adjusted OR, 1.828; 95% CI, 1.218-2.744; P = 0.004) while the TG haplotype was more frequent among health controls (adjusted OR, 0.351; 95% CI, 0.182-0.678; P = 0.002). These findings indicated that polymorphisms of HDC gene were significantly associated with breast cancer in Chinese Han population and may be novel diagnostic or therapeutic targets for breast cancer. Further studies with larger participants worldwide are still needed for conclusion validation.

Indexed as

Genetic Association StudiesPolymorphism, Single NucleotideAdultAllelesBreast NeoplasmsCarcinoma, Ductal, BreastChinaFemaleGenetic Predisposition to DiseaseGenotypeHistamine N-MethyltransferaseHistidine DecarboxylaseHumansMiddle AgedReceptors, Histamine H3Histamine N-MethyltransferaseHistidine DecarboxylaseReceptors, Histamine H3

Identifiers

PMID24835231
PMCPMC4023951
OpenAlexW2050925178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.